FLT4 and neoplasm: We and others showed previously that selective inhibition of the VEGFR-3 pathway with the RTK inhibitor SAR131675 affected the TME, reduced lymphangiogenesis, decreased immunosuppressive cell populations, and thus led to reduction of tumor growth and metastasis (26–28).